Literature DB >> 18838481

Stereochemistry of an agonist determines coupling preference of beta2-adrenoceptor to different G proteins in cardiomyocytes.

Anthony Yiu-Ho Woo1, Tian-Bing Wang, Xiaokun Zeng, Weizhong Zhu, Darrell R Abernethy, Irving W Wainer, Rui-Ping Xiao.   

Abstract

A fundamental question regarding receptor-G protein interaction is whether different agonists can lead a receptor to different intracellular signaling pathways. Our previous studies have demonstrated that although most beta(2)-adrenoceptor agonists activate both G(s) and G(i) proteins, fenoterol, a full agonist of beta(2)-adrenoceptor, selectively activates G(s) protein. Fenoterol contains two chiral centers and may exist as four stereoisomers. We have synthesized a series of stereoisomers of fenoterol and its derivatives and characterized their receptor binding and pharmacological properties. We tested the hypothesis that the stereochemistry of an agonist determines selectivity of receptor coupling to different G protein(s). We found that the R,R isomers of fenoterol and methoxyfenoterol exhibited more potent effects to increase cardiomyocyte contraction than their S,R isomers. It is noteworthy that although (R,R)-fenoterol and (R,R)-methoxyfenoterol preferentially activate G(s) signaling, their S,R isomers were able to activate both G(s) and G(i) proteins as evidenced by the robust pertussis toxin sensitivities of their effects on cardiomyocyte contraction and on phosphorylation of extracellular signal-regulated kinase 1/2. The differential G protein selectivities of the fenoterol stereoisomers were further confirmed by photoaffinity labeling studies on G(s),G(i2), and G(i3) proteins. The inefficient G(i) signaling with the R,R isomers is not caused by the inability of the R,R isomers to trigger the protein kinase A (PKA)-mediated phosphorylation of the beta(2)-adrenoceptor, because the R,R isomers also markedly increased phosphorylation of the receptor at serine 262 by PKA. We conclude that in addition to receptor subtype and phosphorylation status, the stereochemistry of a given agonist plays an important role in determining receptor-G protein selectivity and downstream signaling events.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18838481      PMCID: PMC2654765          DOI: 10.1124/mol.108.051078

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  40 in total

1.  The enigma of beta2-adrenergic receptor Gi signaling in the heart: the good, the bad, and the ugly.

Authors:  Weizhong Zhu; Xiaokun Zeng; Ming Zheng; Rui-Ping Xiao
Journal:  Circ Res       Date:  2005-09-16       Impact factor: 17.367

2.  Crosstalk of beta-adrenergic receptor subtypes through Gi blunts beta-adrenergic stimulation of L-type Ca2+ channels in canine heart failure.

Authors:  Jia-Qiang He; Ravi C Balijepalli; Robert A Haworth; Timothy J Kamp
Journal:  Circ Res       Date:  2005-08-11       Impact factor: 17.367

3.  Enantioselective separation and online affinity chromatographic characterization of R,R- and S,S-fenoterol.

Authors:  Farideh Beigi; Carlo Bertucci; Weizhong Zhu; Khalid Chakir; Irving W Wainer; Rui-Ping Xiao; Darrell R Abernethy
Journal:  Chirality       Date:  2006-11       Impact factor: 2.437

4.  Differential phosphorylation and dephosphorylation of beta2-adrenoceptor sites Ser262 and Ser355,356.

Authors:  Varsha Iyer; Tuan M Tran; Estrella Foster; Wenping Dai; Richard B Clark; Brian J Knoll
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

5.  beta-arrestin-dependent, G protein-independent ERK1/2 activation by the beta2 adrenergic receptor.

Authors:  Sudha K Shenoy; Matthew T Drake; Christopher D Nelson; Daniel A Houtz; Kunhong Xiao; Srinivasan Madabushi; Eric Reiter; Richard T Premont; Olivier Lichtarge; Robert J Lefkowitz
Journal:  J Biol Chem       Date:  2005-11-09       Impact factor: 5.157

Review 6.  Emerging concepts and therapeutic implications of beta-adrenergic receptor subtype signaling.

Authors:  Ming Zheng; Weizhong Zhu; Qide Han; Rui-Ping Xiao
Journal:  Pharmacol Ther       Date:  2005-06-24       Impact factor: 12.310

7.  Pharmacological stimulation of beta2-adrenergic receptors (beta2AR) enhances therapeutic effectiveness of beta1AR blockade in rodent dilated ischemic cardiomyopathy.

Authors:  Ismayil Ahmet; Edward G Lakatta; Mark I Talan
Journal:  Heart Fail Rev       Date:  2005-12       Impact factor: 4.214

8.  Cardioprotective and survival benefits of long-term combined therapy with beta2 adrenoreceptor (AR) agonist and beta1 AR blocker in dilated cardiomyopathy postmyocardial infarction.

Authors:  Ismayil Ahmet; Melissa Krawczyk; Weizhong Zhu; Anthony Yiu-Ho Woo; Christopher Morrell; Suresh Poosala; Riu-Ping Xiao; Edward G Lakatta; Mark I Talan
Journal:  J Pharmacol Exp Ther       Date:  2008-02-20       Impact factor: 4.030

9.  Coupling of the human A1 adenosine receptor to different heterotrimeric G proteins: evidence for agonist-specific G protein activation.

Authors:  Yolande Cordeaux; Adriaan P Ijzerman; Stephen J Hill
Journal:  Br J Pharmacol       Date:  2004-08-09       Impact factor: 8.739

10.  Coupling of beta2-adrenoceptor to Gi proteins and its physiological relevance in murine cardiac myocytes.

Authors:  R P Xiao; P Avdonin; Y Y Zhou; H Cheng; S A Akhter; T Eschenhagen; R J Lefkowitz; W J Koch; E G Lakatta
Journal:  Circ Res       Date:  1999 Jan 8-22       Impact factor: 17.367

View more
  47 in total

Review 1.  β-Adrenergic receptor subtype signaling in heart: from bench to bedside.

Authors:  Anthony Yiu Ho Woo; Rui-ping Xiao
Journal:  Acta Pharmacol Sin       Date:  2012-01-30       Impact factor: 6.150

Review 2.  Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.

Authors:  Terry Kenakin; Laurence J Miller
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

Review 3.  Ensemble of G protein-coupled receptor active states.

Authors:  P S-H Park
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

4.  {Beta}2-adrenergic receptor agonists inhibit the proliferation of 1321N1 astrocytoma cells.

Authors:  L Toll; L Jimenez; N Waleh; K Jozwiak; A Y-H Woo; R-P Xiao; M Bernier; I W Wainer
Journal:  J Pharmacol Exp Ther       Date:  2010-11-11       Impact factor: 4.030

5.  Cannabinoid receptor activation correlates with the proapoptotic action of the β2-adrenergic agonist (R,R')-4-methoxy-1-naphthylfenoterol in HepG2 hepatocarcinoma cells.

Authors:  Rajib K Paul; Anuradha Ramamoorthy; Jade Scheers; Robert P Wersto; Lawrence Toll; Lucita Jimenez; Michel Bernier; Irving W Wainer
Journal:  J Pharmacol Exp Ther       Date:  2012-07-09       Impact factor: 4.030

Review 6.  The year in G protein-coupled receptor research.

Authors:  Robert P Millar; Claire L Newton
Journal:  Mol Endocrinol       Date:  2009-12-17

7.  β2-Adrenoceptor-mediated regulation of glucose uptake in skeletal muscle--ligand-directed signalling or a reflection of system complexity?

Authors:  Bronwyn A Evans; Dana S Hutchinson; Roger J Summers
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-05-09       Impact factor: 3.000

Review 8.  Advances in receptor conformation research: the quest for functionally selective conformations focusing on the β2-adrenoceptor.

Authors:  Anthony Yiu-Ho Woo; Ying Song; Weizhong Zhu; Rui-Ping Xiao
Journal:  Br J Pharmacol       Date:  2015-02-27       Impact factor: 8.739

9.  Comparative molecular field analysis of fenoterol derivatives interacting with an agonist-stabilized form of the β₂-adrenergic receptor.

Authors:  Anita Plazinska; Karolina Pajak; Ewelina Rutkowska; Lucita Jimenez; Joseph Kozocas; Gary Koolpe; Mary Tanga; Lawrence Toll; Irving W Wainer; Krzysztof Jozwiak
Journal:  Bioorg Med Chem       Date:  2013-11-23       Impact factor: 3.641

10.  Quantitative modeling of GRK-mediated beta2AR regulation.

Authors:  Sharat J Vayttaden; Jacqueline Friedman; Tuan M Tran; Thomas C Rich; Carmen W Dessauer; Richard B Clark
Journal:  PLoS Comput Biol       Date:  2010-01-22       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.